151 related articles for article (PubMed ID: 15958627)
1. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.
Gribben JG; Ryan DP; Boyajian R; Urban RG; Hedley ML; Beach K; Nealon P; Matulonis U; Campos S; Gilligan TD; Richardson PG; Marshall B; Neuberg D; Nadler LM
Clin Cancer Res; 2005 Jun; 11(12):4430-6. PubMed ID: 15958627
[TBL] [Abstract][Full Text] [Related]
2. Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome P450 1B1.
Luby TM; Cole G; Baker L; Kornher JS; Ramstedt U; Hedley ML
Clin Immunol; 2004 Jul; 112(1):45-53. PubMed ID: 15207781
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
5. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy of solid tumor: perspectives on vaccine and cell therapy].
Ikeda H; Shiku H
Nihon Rinsho; 2012 Dec; 70(12):2043-50. PubMed ID: 23259373
[TBL] [Abstract][Full Text] [Related]
7. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer.
Tokizane T; Shiina H; Igawa M; Enokida H; Urakami S; Kawakami T; Ogishima T; Okino ST; Li LC; Tanaka Y; Nonomura N; Okuyama A; Dahiya R
Clin Cancer Res; 2005 Aug; 11(16):5793-801. PubMed ID: 16115918
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a single peptide derived from cytochrome P450 1B1 that elicits spontaneous human leukocyte antigen (HLA)-A1 as well as HLA-B35 restricted CD8 T-cell responses in cancer patients.
Kvistborg P; Hadrup SR; Svane IM; Andersen MH; Straten PT
Hum Immunol; 2008; 69(4-5):266-72. PubMed ID: 18486761
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target.
Barnett JA; Urbauer DL; Murray GI; Fuller GN; Heimberger AB
Clin Cancer Res; 2007 Jun; 13(12):3559-67. PubMed ID: 17575219
[TBL] [Abstract][Full Text] [Related]
11. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
Aguilar LK; Guzik BW; Aguilar-Cordova E
J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA regulates the expression of human cytochrome P450 1B1.
Tsuchiya Y; Nakajima M; Takagi S; Taniya T; Yokoi T
Cancer Res; 2006 Sep; 66(18):9090-8. PubMed ID: 16982751
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 1B1: a novel anticancer therapeutic target.
McFadyen MC; Murray GI
Future Oncol; 2005 Apr; 1(2):259-63. PubMed ID: 16555997
[TBL] [Abstract][Full Text] [Related]
15. Universal tumor antigens as targets for immunotherapy.
Gordan JD; Vonderheide RH
Cytotherapy; 2002; 4(4):317-27. PubMed ID: 12396831
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 1B1 is required for 7,12-dimethylbenz(a)-anthracene (DMBA) induced spleen cell immunotoxicity.
Gao J; Lauer FT; Dunaway S; Burchiel SW
Toxicol Sci; 2005 Jul; 86(1):68-74. PubMed ID: 15843505
[TBL] [Abstract][Full Text] [Related]
17. Induction of CYP1A1 and CYP1B1 and formation of carcinogen-DNA adducts in normal human mammary epithelial cells treated with benzo[a]pyrene.
Keshava C; Divi RL; Whipkey DL; Frye BL; McCanlies E; Kuo M; Poirier MC; Weston A
Cancer Lett; 2005 Apr; 221(2):213-24. PubMed ID: 15808407
[TBL] [Abstract][Full Text] [Related]
18. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.
Gjerstorff MF; Burns J; Ditzel HJ
Expert Opin Biol Ther; 2010 Jul; 10(7):1061-75. PubMed ID: 20420535
[TBL] [Abstract][Full Text] [Related]
19. Targeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine.
Luby TM
Expert Rev Vaccines; 2008 Sep; 7(7):995-1003. PubMed ID: 18767949
[TBL] [Abstract][Full Text] [Related]
20. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
Park JW; Melisko ME; Esserman LJ; Jones LA; Wollan JB; Sims R
J Clin Oncol; 2007 Aug; 25(24):3680-7. PubMed ID: 17704416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
